Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06480526 · ClinicalTrials.gov registry record
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
A clinical trial of High-risk Neuroblastoma, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT06480526 is a study of High-risk Neuroblastoma that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 45 participants, below the 60-participant average among 9 other High-risk Neuroblastoma trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06480526, a study of High-risk Neuroblastoma, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL). Primary Objective To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) study infrastructure, in survivors of HR-NBL (high-risk neuroblastoma) who are greater than 2 years from completion of contemporary therapy and were previously treated at SJCRH (St. Jude Children's Research Hospital). Exploratory Objectives * To describe the health outcomes of survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy. * To describe the relationship between patient outcomes and social determinants of health (SDOH) in survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy.
Conditions Studied
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06480526
The ClinicalTrials.gov registry entry for NCT06480526 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 60-participant average among 9 other High-risk Neuroblastoma trials with a reported enrollment target (25% lower). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High-risk Neuroblastoma appearing as the primary indexed condition, and to 0 interventions.
NCT06480526 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06480526 about?
NCT06480526 is a clinical study titled "Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors". The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL). Primary Objective To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) st...
What is the current status of trial NCT06480526?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2024-10-21. Estimated completion is 2028-12.
What conditions does trial NCT06480526 study?
This clinical trial studies the following conditions: High-risk Neuroblastoma.
Who is sponsoring clinical trial NCT06480526?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06480526 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High-risk Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
-
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
RECRUITING · Phase 2
-
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
RECRUITING · NA
-
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
RECRUITING · Phase 2
-
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.